caa a22 4500 605492921 CHVBK 20210128100518.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s00261-015-0353-8 doi (NATIONALLICENCE)springer-10.1007/s00261-015-0353-8 Recent advances in image-guided targeted prostate biopsy [Elektronische Daten] [Anna Brown, Osama Elbuluk, Francesca Mertan, Sandeep Sankineni, Daniel Margolis, Bradford Wood, Peter Pinto, Peter Choyke, Baris Turkbey] Prostate cancer is a common malignancy in the United States that results in over 30,000 deaths per year. The current state of prostate cancer diagnosis, based on PSA screening and sextant biopsy, has been criticized for both overdiagnosis of low-grade tumors and underdiagnosis of clinically significant prostate cancers (Gleason score ≥7). Recently, image guidance has been added to perform targeted biopsies of lesions detected on multi-parametric magnetic resonance imaging (mpMRI) scans. These methods have improved the ability to detect clinically significant cancer, while reducing the diagnosis of low-grade tumors. Several approaches have been explored to improve the accuracy of image-guided targeted prostate biopsy, including in-bore MRI-guided, cognitive fusion, and MRI/transrectal ultrasound fusion-guided biopsy. This review will examine recent advances in these image-guided targeted prostate biopsy techniques. Springer Science+Business Media New York (outside the USA), 2015 Prostate cancer nationallicence Biopsy nationallicence Targeted nationallicence MRI nationallicence TRUS nationallicence Brown Anna Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut Elbuluk Osama Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut Mertan Francesca Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut Sankineni Sandeep Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut Margolis Daniel David Geffen School of Medicine at UCLA, Los Angeles, CA, USA aut Wood Bradford Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD, USA aut Pinto Peter Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD, USA aut Choyke Peter Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut Turkbey Baris Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut Abdominal Imaging Springer US; http://www.springer-ny.com 40/6(2015-08-01), 1788-1799 0942-8925 40:6<1788 2015 40 261 https://doi.org/10.1007/s00261-015-0353-8 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00261-015-0353-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Brown Anna Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Elbuluk Osama Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Mertan Francesca Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Sankineni Sandeep Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Margolis Daniel David Geffen School of Medicine at UCLA, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Wood Bradford Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Pinto Peter Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Choyke Peter Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Turkbey Baris Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA aut NATIONALLICENCE 773 0- Abdominal Imaging Springer US; http://www.springer-ny.com 40/6(2015-08-01), 1788-1799 0942-8925 40:6<1788 2015 40 261